LivaNova (Nasdaq:LIVN) this week posted fourth-quarter results that beat the overall consensus on Wall Street.
The London-based company reported profits of $1.7 million, or 3¢ per share, on sales of $274.9 million for the three months ended Dec. 31, 2022, for a sales gain of 1.78% compared with Q4 2021. It also had a profit gain over the same quarter in 2021 when it reported profit losses of $5.1 million.
Adjusted to exclude one-time items, earnings per share were 81¢, 8¢ ahead of The Street, where analysts were looking for sales of $262.58 million.
“We delivered revenue growth across all regions in the fourth quarter, excluding foreign currency impact, led by our Cardiopulmonary and Neuromodulation business units,” CEO Damien McDonald said in a news release. “In 2023, we remain committed to executing on our core growth drivers, delivering on clinical and product pipeline opportunities, and driving operating leverage to improve cash flow.”
For the full-year 2023, LivaNova anticipates revenue to grow in the range of 3-5% on a constant-currency basis. Non-GAAP earnings per share for fiscal 2023 are expected to be in the range of $2.45-$2.65.
Shares in LIVN were at a standstill in premarket hours.